Callan Capital’s Poseida Therapeutics PSTX Stock Holding History
Bought
Maintained
Sold
Other funds holding PSTX
Callan Capital's PSTX Position: Q4 2024 in Review
Callan Capital sold out of Poseida Therapeutics (PSTX) in Q4 2024, closing a stake of 108,080 shares — an estimated $309K sold.
Callan Capital first reported a position in PSTX in Q4 2022 and held it in 8 quarters. The position peaked at $330K in Q4 2022. 115 funds tracked by Wall St. Rank hold PSTX as of Q4 2024.
- Callan Capital reported no remaining Poseida Therapeutics position as of Q4 2024 after selling out during the quarter.
- Callan Capital sold 108,080 Poseida Therapeutics shares in Q4 2024, an estimated $309K.
- Callan Capital first reported a position in Poseida Therapeutics in Q4 2022 and held it in 8 quarters.
- Callan Capital's Poseida Therapeutics position peaked at $330K in Q4 2022.
- 115 funds tracked by Wall St. Rank held Poseida Therapeutics as of Q4 2024.
Based on Callan Capital's 13F filing for Q4 2024, filed 3 Feb 2025.